Active, not recruitingPhase 2NCT06208748

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sarcoma Alliance for Research through Collaboration
Principal Investigator
Candace Haddox, MD
Dana-Farber Cancer Institute
Intervention
Bezuclastinib in combination with sunitinib(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
20242027

Study locations (4)

Collaborators

Cogent Biosciences, Inc. · Dana-Farber Cancer Institute · The Life Raft Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06208748 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor

← Back to all trials